P. Bunn

发表

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

J. Crowley, K. Kelly, P. Bunn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23).

J. Minna, A. Gazdar, J. Whang‐Peng, 1982, Science.

Epidermal growth factor receptor family in lung cancer and premalignancy.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma.

J. Weinstein, S. Larson, P. Bunn, 1987, Cancer research.

Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody.

J. Weinstein, S. Larson, J. Mulshine, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

V. Rusch, Bruce E. Johnson, I. Wistuba, 2019, Journal of Clinical Oncology.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

M. Kris, V. Rusch, Bruce E. Johnson, 2018 .

Functional Genomics of Lung Disease

S. Redline, N. Friedman, A. Regev, 2004 .

Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells.

J. Minna, A. Gazdar, A. Gazdar, 1985, Blood.

Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways.

P. Bunn, T. Puck, M. Tagawa, 1990, Proceedings of the National Academy of Sciences of the United States of America.

T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas.

Ilan R. Kirsch, Bruce E. Johnson, P. Bunn, 1985, The New England journal of medicine.

Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment?

K. Kelly, P. Bunn, J. Mault, 2000, Chest.

To Treat or Not to Treat Non–Small-Cell Lung Cancer Patients? Current Perspectives

P. Bunn, 1999 .

New Drug Combinations in NSCLC: Progress in Cancer Therapy

P. Bunn, A. Soriano, 1999 .

Volatile fingerprints of cancer specific genetic mutations.

Radu Ionescu, Ulrike Tisch, Hossam Haick, 2013, Nanomedicine : nanotechnology, biology, and medicine.

Classification of lung cancer histology by gold nanoparticle sensors.

Ulrike Tisch, Hossam Haick, Orna Barash, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Non-invasive Breath Analysis of Pulmonary Nodules

H. Haick, Y. Miller, F. Hirsch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

7.1.1 Invited: Chemical Nanoarrays for Early Detection and Screening of Lung Cancer via Volatile Biomarkers

H. Haick, Y. Miller, F. Hirsch, 2012 .

Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.

A. Gazdar, F. Hirsch, P. Bunn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival.

R. Makuch, A. Gazdar, P. Bunn, 1980, Journal of the National Cancer Institute.

2020 Innovation Based Optimism for Lung Cancer Outcomes.

Erin L. Schenk, P. Bunn, E. Schenk, 2020, The oncologist.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells.

B. Haynes, J. Minna, P. Bunn, 1981, The New England journal of medicine.

Future directions in clinical research for lung cancer.

P. Bunn, 1994, Chest.

Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.

D. Longo, P. Bunn, S. Averbuch, 1984, The New England journal of medicine.

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.

D. Longo, P. Bunn, K. Foon, 1984, Annals of internal medicine.

Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia.

P. Bunn, K. Foon, M. Roth, 1986, Seminars in oncology.

Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.

P. Bunn, K. Foon, 1986, Seminars in oncology.

Interferon therapy of non‐Hodgkin's lymphoma

P. Bunn, K. Foon, M. Roth, 1987, Cancer.

Growth factors in lung cancer: possible etiologic role and clinical target.

K. Kelly, P. Bunn, M. Kane, 1991, Medical and pediatric oncology.

Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.

P. Bunn, L. Heasley, B. Helfrich, 1998, Cancer research.

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

P. Bunn, D. Raben, D. Chan, 2002, Seminars in oncology.

Small Cell Bronchogenic Carcinoma: A Review of Therapeutic Results

P. Bunn, D. Ihde, 1981 .

Future directions in the management of non-small cell lung cancer

P. Bunn, 1993 .

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

M. Ladanyi, A. Iafrate, M. Kris, 2015, Cancer.

Results of therapeutic cranial irradiation in small cell lung cancer.

J. Carmichael, P. Bunn, E. Glatstein, 1988, International journal of radiation oncology, biology, physics.

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations

P. Bunn, E. Schenk, J. Pacheco, 2021, JNCI cancer spectrum.

Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

P. Bunn, J. Pacheco, 2019, Clinical lung cancer.

Chemotherapy rather than demeclocycline for inappropriate secretion of antidiuretic hormone.

J. Minna, P. Bunn, D. Ihde, 1978, The New England journal of medicine.

New treatment agents for advanced small cell and non-small cell lung cancer.

K. Kelly, P. Bunn, Karen Kelly, 1995, Seminars in oncology.

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

F. Hirsch, P. Bunn, R. Dziadziuszko, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.

P. Bunn, R. Doebele, D. Aisner, 2016, Lung cancer.

Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision.

P. Bunn, D. Aisner, 2018, JAMA.

High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts)

F. Hirsch, P. Bunn, W. Franklin, 2007 .

The human T-cell leukemia-lymphoma virus in the southeastern United States.

E. Jaffe, R. Fisher, P. Bunn, 1983, JAMA.

DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sézary syndrome.

A. Gazdar, J. Whang‐Peng, P. Bunn, 1980, The Journal of clinical investigation.

New combinations in the treatment of lung cancer: a time for optimism.

K. Kelly, P. Bunn, 2000, Chest.

Chemotherapeutic options in lung cancer

P. Bunn, A. Soriano, 1998 .

A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer.

K. Kelly, P. Bunn, M. Hazuka, 1998, International journal of radiation oncology, biology, physics.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2002, Clinical breast cancer.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

N. Hanna, P. Bunn, P. Ellis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New anti‐lung‐cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma

P. Bunn, W. Franklin, K. Christensen, 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

The evolution of tumor classification: a role for genomics?

P. Bunn, W. Franklin, R. Doebele, 2013, Cancer cell.

Chemoprevention of lung cancer--from biology to clinical reality.

F. Hirsch, P. Bunn, W. Franklin, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, M. Ladanyi, A. Iafrate, 2013 .

Methods for production of monoclonal antibodies with specificity for human lung cancer cells

J. Minna, A. Gazdar, P. Bunn, 1981, In Vitro.

Irinotecan and platinums in the treatment of non small-cell lung cancer.

P. Bunn, 2001, Clinical lung cancer.

Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.

E. Sausville, R. Makuch, A. Gazdar, 1985, Human pathology.

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2006, Clinical Cancer Research.

Herpes zoster and small cell bronchogenic carcinoma.

J. Minna, P. Bunn, D. Ihde, 1980, The American journal of medicine.

Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy.

J. Minna, P. Bunn, D. Ihde, 1979, Radiology.

Prevention, early detection and screening

P. Bunn, H. Hansen, 2005 .

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

G. Scagliotti, H. Wakelee, F. Hirsch, 2022, Journal of Thoracic Oncology.

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

F. Hirsch, P. Bunn, F. Hirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IASLC Textbook of Prevention and Early Detection of Lung Cancer

H. Kato, F. Hirsch, J. Mulshine, 2005 .

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized study of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients

Y. Miller, F. Hirsch, P. Bunn, 2000 .

High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum.

T. Byers, Y. Miller, T. Petty, 2004, Chest.

Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.

A. Klein-Szanto, G. Piazza, P. Bunn, 2003, Molecular cancer therapeutics.

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism

J. Stewart, P. Bunn, T. Puck, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum.

F. Hirsch, D. Carbone, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Origin of human small cell lung cancer.

J. Minna, A. Gazdar, P. Bunn, 1985, Science.

Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

N. Hanna, P. Bunn, P. Ellis, 2005 .

A COMPARISON OF COMPUTED TOMOGRAPHY AND RADIONUCLIDE SCANNING FOR DETECTION OF BRAIN METASTASES IN SMALL CELL LUNG CANCER

R. Makuch, P. Bunn, E. Glatstein, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.

A. Malkinson, A. Gazdar, P. Bunn, 1992, Cancer research.

S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results

R. Ginsberg, P. Bunn, D. Gandara, 2005 .

S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial

J. Crowley, R. Ginsberg, P. Bunn, 2007 .

Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer

J. Minna, J. Whang‐Peng, P. Bunn, 1982 .

Serial fiberoptic bronchoscopy during chemotherapy for small cell carcinoma of the lung: early detection of patients at high risk of relapse.

J. Minna, P. Bunn, D. Ihde, 1978, Chest.

Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer.

R. Makuch, J. Minna, P. Bunn, 1986, The American journal of medicine.

Reply to A. Braillon.

P. Bunn, J. Schiller, David H. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P2-073: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated patients with non-small cell lung cancer (NSCLC)

F. Hirsch, P. Bunn, R. Dziadziuszko, 2007 .

Neoadjuvant combination chemotherapy for unresectable stage III non–small cell lung cancer

P. Bunn, John D. Mitchell, M. Weyant, 2016, Cancer.

Single-Institution Experience with Pemetrexedand Bevacizumab as Salvage Therapy in AdvancedNon–Small-Cell Lung Cancer

K. Kelly, P. Bunn, G. Weiss, 2007 .

Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model

Raphael A Nemenoff, L. Dwyer-Nield, A. Malkinson, 2010 .

Small-cell carcinoma of lung: reinduction therapy after late relapse.

P. Bunn, G. Batist, D. Carney, 1983, Annals of internal medicine.

Chemotherapy: Adjuvant TKIs in NSCLC: what can we learn from RADIANT?

F. Hirsch, P. Bunn, 2015, Nature Reviews Clinical Oncology.

A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.

K. Kelly, P. Bunn, S. Prindiville, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.

R. Makuch, J. Minna, J. Whang‐Peng, 1985, Annals of internal medicine.

Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.

R. Makuch, J. Minna, P. Bunn, 1979, Cancer treatment reports.

Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.

R. Abrams, R. Makuch, P. Bunn, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Testing for Lung Cancer: Reflex vs. Clinical Selection

P. Bunn, R. Doebele, 2016 .

EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib.

F. Hirsch, T. Mitsudomi, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.

G. Scagliotti, P. Bunn, J. Denne, 2017, Lung cancer.

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

F. Hirsch, P. Bunn, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.

F. Hirsch, P. Bunn, D. Gandara, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Miklos Pless, N. Hanna, C. Desch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Setting a new mesothelioma treatment standard

P. Bunn, B. Solomon, 2005 .

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.

P. Bunn, B. Solomon, 2005, Future oncology.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Kenneth L. Jones, P. Bunn, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

F. Hirsch, C. Watkins, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment

F. Hirsch, P. Bunn, D. Gandara, 2005 .

An update on North American randomized studies in non-small cell lung cancer.

P. Bunn, E. Vokes, J. Schiller, 1998, Seminars in oncology.

Small cell lung cancer 1973-1983: early progress and recent obstacles.

J. Minna, P. Bunn, D. Carney, 1984, International journal of radiation oncology, biology, physics.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

M. Kris, G. Sica, I. Wistuba, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of the National Cancer Institute.

Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal.

F. Hirsch, P. Bunn, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126)

F. Hirsch, P. Bunn, D. Gandara, 2005 .

lung cancer will improve personalized care and provide patients with therapy that is most likely to improve their disease.

P. Bunn, R. Doebele, 2011 .

Reply to M.C. Garassino et al

P. Bunn, R. Doebele, 2011 .

Advances in small cell bronchogenic carcinoma.

J. Minna, P. Bunn, D. Ihde, 1977, Cancer treatment reports.

European School of Oncology. First Euro-American Forum on Lung Cancer Treatment.

U. Pastorino, P. Bunn, U. Gatzemeier, 1994, European journal of cancer.

J. Minna, A. Gazdar, P. Bunn, 2006 .

Novel Agents in the Treatment of Lung Cancer

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical Cancer Research.

Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH)

F. Hirsch, P. Bunn, W. Franklin, 2000 .

C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo

F. Hirsch, P. Bunn, W. Franklin, 2001 .

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, A. Gazdar, F. Hirsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib sensitivity in non-small cell lung cancer (NSCLC) cell lines associates with mutation and amplification of the epidermal growth factor receptor (EGFR) gene

J. Minna, M. Peyton, A. Gazdar, 2005 .

Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)

F. Hirsch, C. Watkins, P. Bunn, 2007 .

Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

Discordant Signal Transduction and Growth Inhibition of Small Cell Lung Carcinomas Induced by Expression of GTPase-deficient G(*)

P. Bunn, L. Heasley, G. Johnson, 1996, The Journal of Biological Chemistry.

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo

P. Bunn, D. Gao, Jihye Kim, 2016, Molecular Cancer Therapeutics.

Recent clinical advances in lung cancer management.

P. Bunn, J. Schiller, David H. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination cancer chemotherapy with one compound: Pluripotent bradykinin antagonists

E. York, J. Stewart, P. Bunn, 2005, Peptides.

Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging.

J. Weinstein, S. Larson, J. Mulshine, 1987, Cancer research.

Anti-growth factor therapy for lung cancer.

P. Bunn, M. Geraci, D. Chan, 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

V. Devita, P. Bunn, P. Banks, 1976, Blood.

Platinums in lung cancer: sufficient or necessary?

P. Bunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.

J. Stewart, P. Bunn, Kenneth K. Chan, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Controversies in the nonsurgical treatment of stage III non-small cell lung cancer.

P. Bunn, M. Hazuka, 1992, The American review of respiratory disease.

Role of radiation therapy in small cell anaplastic carcinoma of the lung.

R. Wittes, P. Bunn, N. Bleehen, 1983, Cancer treatment reports.

Lessons learned from the systematic evaluation of cutaneous T-cell lymphomas at the national cancer institute and the roadmap for future studies.

P. Bunn, T. Pacheco, 2010, Clinical lymphoma, myeloma & leukemia.

T‐Cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T‐cell lymphomas (CTCL) and adult T‐cell leukemia‐lymphomas (ATLL)

P. Bunn, F. Foss, 1996, Journal of cellular biochemistry. Supplement.

The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas.

P. Bunn, D. Norris, David A. Norris, 1990, The Journal of investigative dermatology.

Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody.

A. Gazdar, J. Mulshine, P. Bunn, 1986, The New England journal of medicine.

IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODY

S. Larson, A. Gazdar, P. Bunn, 1984, The Lancet.

Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma.

J. Weinstein, E. Sausville, J. Herdt, 1991, Cancer research.

Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.

J. Mulshine, P. Bunn, K. Foon, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Imaging, Pharmacokinetics, Dosimetry and Antitumor Effects of Radiolabeled Anti-Breast Cancer Antibodies in Mouse and Man

P. Bunn, R. Ceriani, G. Miller, 1991 .

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

F. Cappuzzo, F. Hirsch, P. Bunn, 2005, British Journal of Cancer.

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

H. Ji, F. Hirsch, P. Bunn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

G. Scagliotti, H. Wakelee, F. Hirsch, 2021, JTO Clinical and Research Reports.

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus.

T. Waldmann, E. Jaffe, V. Devita, 1984, Annals of internal medicine.

The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma.

E. Jaffe, D. Longo, P. Bunn, 1983, Blood.

Cutaneous T-cell lymphoma: A review

P. Bunn, R. Edelson, C. F. Winkler, 1983 .

Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

P. Bunn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy

N. Hanna, P. Bunn, F. Shepherd, 2003 .

Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites.

Y. Miller, P. Bunn, W. Franklin, 1996, American journal of respiratory cell and molecular biology.

Abdominal computed tomography in small cell lung cancer: Assessment of extent of disease and response to therapy

J. Minna, P. Bunn, Martin H. Cohen, 1982 .

of the Malignant T Cell in Sezary Syndrome and Mycosis Fungoides

Charles R. Thomas, B. Haynes, J. Minna, 1981 .

Baseline and On‐Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene‐Addicted Adenocarcinoma of the Lung

P. Bunn, R. Camidge, R. Doebele, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

C. Henschke, D. Yankelevitz, J. Minna, 2022, Cancer Cell.

Indium-i 11 TiOl Monoclonal Antibody @maging is Superior to Iodine-13 1 T 10 1 in I of Cutaneous T-Cell Lymphoma

P. Bunn, J. Carrasquillo, Steven, 2006 .

Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody.

P. Bunn, T. Lindmo, J. Mitchell, 1985, Cancer research.

Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy.

P. Bunn, R. Ceriani, J. Lear, 1992, Radiology.

Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling.

P. Bunn, T. Lindmo, 1986, Methods in enzymology.

Monoclonal Antibody Therapy for Patients with Leukemia and Lymphoma

P. Bunn, K. Foon, R. Schroff, 1985 .

Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia.

D. Carlo, P. Bunn, K. Foon, 1984, Blood.

Immunolymphoscintigraphyin Patients with Lymphoma After SubcutaneousInjection of Indium-111-LabeledT 101 Monoclonal Antibody

J. Weinstein, S. Larson, J. Mulshine, 1987 .

Selective cytotoxicity of 125I-labeled monoclonal antibody T101 in human malignant T cell lines.

P. Bunn, T. Lindmo, J. Mitchell, 1986, Blood.

Patterns of cell proliferation and cell migration in the Sézary syndrome.

P. Bunn, S. Shackney, R. Edelson, 1981, Blood.

What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer?

F. Hirsch, P. Bunn, W. Franklin, 2002, Lung cancer.

Combination chemotherapy with doxorubicin and mitomycin C in non small cell bronchogenic carcinoma: Severe pulmonary toxicity from q 3 weekly mitomycin C

J. Minna, P. Bunn, L. Doyle, 1984, American journal of clinical oncology.

Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients.

A. Gazdar, P. Bunn, D. Carney, 1982, Stem cells.

Lung cancer. Introduction.

G. Giaccone, F. Hirsch, P. Bunn, 2003, Lung cancer.

RET rearrangements detected by FISH in "pan-negative" lung adenocarcinoma.

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013 .

The expanding role of cisplatin in the treatment of non-small-cell lung cancer.

P. Bunn, 1989, Seminars in oncology.

Clinical experiences with carboplatin (paraplatin) in lung cancer.

P. Bunn, 1992, Seminars in oncology.

A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1995, Seminars in oncology.

Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Y. Miller, P. Bunn, W. Franklin, 1996, Cancer research.

Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas.

J. Minna, A. Gazdar, P. Bunn, 1979, Cancer treatment reports.

Lymphocyte transformation in patients with cutaneous T‐cell lymphomas

A. Gazdar, P. Bunn, D. Carney, 1980, International journal of cancer.

The Potential Role of Proteasome Inhibitors in the Treatment of Lung Cancer

P. Bunn, 2004, Clinical Cancer Research.

Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas.

E. Jaffe, A. Gazdar, P. Bunn, 1980, Blood.

Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column.

T. K. Johnson, P. Bunn, J. Lear, 1991, Radiology.

Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts.

P. Bunn, P. Furmanski, J. Lear, 1990, Cancer research.

HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.

P. Bunn, W. Franklin, R. Ozols, 2000, Seminars in oncology.

Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?

P. Bunn, 1995, Archives of Dermatology.

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

M. Kris, V. Rusch, I. Wistuba, 2021 .

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.

J. Minna, G. Scagliotti, R. Govindan, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

M. Kris, V. Rusch, I. Wistuba, 2022, Nature Medicine.

E. York, J. Stewart, P. Bunn, 2002, Canadian journal of physiology and pharmacology.

Metabolism-Resistant Bradykinin Antagonists: Development and Applications

E. York, J. Stewart, P. Bunn, 2001, Biological chemistry.

Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.

P. Bunn, S. Rosen, E. Kaplan, 1990, Journal of the National Cancer Institute.

67Ga accumulation in pulmonary lesions associated with bleomycin toxicity

G. Johnston, P. Bunn, S. Levenson, 1975 .

Carcinomatous Leptomeningitis in Small Cell Lung Cancer: A Clinicopathologic Review of the National Cancer Institute Experience

R. Makuch, P. Bunn, S. Rosen, 1982, Medicine.

574 Evidence for an endothelin-1 autocrine loop in lung cancer

Y. Miller, P. Bunn, W. Franklin, 1997 .

Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer

Derek E. Smith, P. Bunn, R. Camidge, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Innovative and future approaches to small cell lung cancer treatment.

P. Bunn, M. Kane, L. Beck, 1988, Seminars in oncology.

Bradykinin antagonists: present progress and future prospects.

E. York, J. Stewart, P. Bunn, 1999, Immunopharmacology.

Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.

R. Makuch, P. Bunn, A. Lichter, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune therapy for lung cancer: are we getting closer?

P. Bunn, 1999, American journal of respiratory cell and molecular biology.

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)

M. Kris, V. Rusch, I. Wistuba, 2018, Journal of Thoracic Oncology.

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

P. Bunn, T. Kuzel, S. Rosen, 1990, Journal of the National Cancer Institute.

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

E. Kohn, E. Sausville, D. Longo, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PNEUMONIA IN THE OLDER PATIENT *

P. Bunn, 1968, Journal of the American Geriatrics Society.

Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.

P. Bunn, M. Tagawa, J. Stewart, 1994, Cancer research.

Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity.

P. Bunn, M. Tagawa, P. Jewett, 1992, Cancer research.

Pemetrexed as a single agent in the therapy of advanced lung cancer.

P. Postmus, P. Bunn, 2002, Seminars in oncology.

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.

M. Kris, M. Socinski, J. Minna, 2016 .

Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis

J. Minna, P. Bunn, D. Ihde, 1979 .

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

P. Bunn, A. Navarro, L. Paz-Ares, 2022, Cancer.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

B. Hendriks, J. Fitzgerald, P. Bunn, 2017, Anti-cancer drugs.

Future directions in the development of pemetrexed.

P. Bunn, H. Calvert, 2002, Seminars in oncology.

Blood and lymph node T lymphocytes in cutaneous T cell lymphoma: evaluation by light microscopy.

J. Minna, P. Bunn, A. Fischmann, 1979, Cancer treatment reports.

Small-cell lung cancer: what we know, what we need to know and the path forward

J. Minna, A. Gazdar, P. Bunn, 2017, Nature Reviews Cancer.

Chemotherapy in small cell lung cancer: a consensus report

M. Fukuoka, P. Bunn, H. Hansen, 1989 .

Pharmacokinetics of In-111 T101 (anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma

S. Larson, J. Mulshine, P. Bunn, 1993 .

Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies.

J. Minna, A. Gazdar, J. Mulshine, 1986, Cancer research.

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1995, Seminars in oncology.

Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines.

F. Hirsch, P. Bunn, D. Chan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed safety and dosing strategy.

P. Bunn, A. Calvert, P. Paoletti, 2002, Seminars in oncology.

Triplet chemotherapy combinations with new agents: is there a rationale?

P. Bunn, 1998, Seminars in oncology.

The Emerging Role of Paclitaxel Plus Carboplatin in Non–Small-Cell Lung Cancer

P. Bunn, 1999 .

Septicemic complications of the cutaneous T-cell lymphomas.

P. Bunn, J. Eddy, B. Fossieck, 1981, The American journal of medicine.

Possible enhancement of vincristine neuropathy by VP‐16

J. Minna, P. Bunn, D. Ihde, 1982, Cancer.

Current therapeutic approaches in lung cancer.

P. Bunn, 2002, Clinical lung cancer.

Triplet combination chemotherapy and targeted therapy regimens.

P. Bunn, 2001, Oncology.

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.

K. Kelly, P. Bunn, 2000, Clinical lung cancer.

A Phase I / II Trial of Paclitaxel , Carboplatin , and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer 1

James D. Murphy, K. Kelly, P. Bunn, 2000 .

The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.

P. Bunn, 1996, Seminars in oncology.

Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib

F. Hirsch, P. Bunn, W. Franklin, 2006 .

The role of routine chest radiotherapy in small-cell lung cancer. An issue of timing and stage.

K. Kelly, P. Bunn, 1993, Chest.

The role of radiation therapy in the treatment of small cell lung cancer

R. Makuch, J. Minna, P. Bunn, 1985, Cancer.

Chapter 18 – NITROSOUREA-CONTAINING COMBINATIONS IN SMALL-CELL LUNG CANCER

P. Bunn, 1981 .

Evaluation of response to chemotherapy with fiberoptic bronchoscopy in non‐small cell lung cancer

J. Minna, P. Bunn, J. Minna, 1980, Cancer.

Skeletal manifestations in cutaneous T-cell lymphomas.

P. Bunn, L. Wahl, G. Schechter, 1982, Archives of dermatology.

Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus

J. Minna, P. Bunn, R. Gallo, 1981, Nature.

Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotype

P. Bunn, B. Mitchell, Y. Sidi, 1985, British journal of haematology.

Purine pathway enzymes in the circulating malignant cells of patients with cutaneous T‐cell lymphoma

P. Bunn, G. Reaman, D. Poplack, 1982, British journal of haematology.

Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.

B. Haynes, J. Minna, A. Fauci, 1981, The Journal of clinical investigation.

Cytogenetic abnormalities in patients with cutaneous T-cell lymphomas.

J. Minna, A. Gazdar, J. Whang‐Peng, 1979, Cancer treatment reports.

Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States.

W. Blattner, E. Jaffe, E. Gelmann, 1985, Journal of the National Cancer Institute.

Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome.

P. Bunn, J. Minna, A. Fischmann, 1979, Cancer treatment reports.

Evidence for human T cell lymphoma-leukemia virus infection of family members of human T cell lymphoma-leukemia virus positive T cell leukemia-lymphoma patients

P. Bunn, Y. Ito, D. Catovsky, 1983, The Journal of experimental medicine.

Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas

P. Bunn, J. Minna, M. Robert-Guroff, 1981, The Journal of experimental medicine.

Lack of efficacy of high-dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung.

J. Minna, P. Bunn, D. Carney, 1982, Cancer treatment reports.

Phase II trial of cisplatin in small cell carcinoma of the lung.

J. Minna, P. Bunn, D. Ihde, 1981, Cancer treatment reports.

327 Phase II trial of induction paclitaxel/carboplatin (PC) in early stage (T2NO, T1-2N1, and selected T3NO-1) non-small cell lung cancer (NSCLC)

M. Kris, R. Ginsberg, P. Bunn, 1997 .

Taxanes in the Treatment of Advanced (Stage III and IV) Non-small Cell Lung Cancer (NSCLC): Recent Developments

P. Bunn, G. Simon, 2003, Cancer investigation.

Simultaneous gastric and plasma immunoreactive plasma carcinoembryonic antigen in 108 patients undergoing gastroscopy.

P. Bunn, J. Minna, M. Cohen, 1979, Gastroenterology.

The effects of colcemid on hematopoiesis in the mouse.

P. Bunn, S. Shackney, S. Ford, 1976, The Journal of clinical investigation.

Fc receptor-defined T-lymphocyte subpopulations in patients with cutaneous T-cell lymphoma.

P. Bunn, D. Munson, G. Schechter, 1982, The Journal of investigative dermatology.

Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus

P. Bunn, H. Mitsuya, S. Broder, 1983, The Journal of experimental medicine.

Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells.

J. Minna, J. Mulshine, P. Bunn, 1987, Cancer research.

Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

Calcitriol levels in hypercalcemic patients with adult T-cell lymphoma.

P. Bunn, M. Williams, C. F. Winkler, 1986, Archives of internal medicine.

Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers.

P. Bunn, A. Dimou, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines.

K. Horwitz, P. Bunn, P. Jewett, 1989, Cancer research.

Lymphokine-induced monocytic differentiation as a possible mechanism for hypercalcemia associated with adult T-cell lymphoma.

P. Bunn, M. Cohen, C. F. Winkler, 1985, Cancer research.

High‐dose methotrexate with leucovorin rescue in patients with unresectable non‐small cell carcinoma of the lung

J. Minna, P. Bunn, J. Minna, 1983, Cancer.

Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

P. Bunn, J. Fedorko, T. Lindmo, 1984, Journal of immunological methods.

In Vivo Studies of Radiolabeled Monoclonal Antibodies Mc5 and KC4 in Human Breast Cancer

P. Bunn, R. Ceriani, G. Miller, 1989 .

A Review of Therapeutic Trials in Multiple Myeloma and Perspectives for Future Trials

P. Bunn, M. Vrana, 1980 .

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Properdin System in Infections and in Malignant Blood Dyscrasias.

P. Bunn, A. Baltch, 1959, Transactions of the American Clinical and Climatological Association.

O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib

F. Hirsch, P. Bunn, W. Franklin, 2005 .

Maximum tolerated dose for low-dose continuous infusion cisplatin.

P. Bunn, M. Hazuka, J. Crowley, 1991, International journal of radiation oncology, biology, physics.

Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.

P. Bunn, L. Einhorn, F. Greco, 1986, Seminars in oncology.

Extracorporeal immunoadsorption of radiolabeled monoclonal antibody: a method for reduction of background radioactivity and its potential role during the radioimmunotherapy of cancer

P. Bunn, G. Miller, S. Glenn, 1994 .

Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.

P. Bunn, 1997, Seminars in oncology.

Recombinant interferon alfa‐2a, an active agent in advanced cutaneous t‐cell lymphomas

P. Bunn, K. Foon, D. Ihde, 1987, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Hepatic involvement in the cutaneous T‐cell lymphomas. Results of percutaneous biopsy and peritoneoscopy

J. Minna, A. Gazdar, P. Bunn, 1980, Cancer.

The kinetics of Sézary cell production.

P. Bunn, S. Shackney, R. Edelson, 1979, Cancer treatment reports.

Manifestations of cutaneous T-cell lymphoma.

P. Bunn, D. Carney, 1980, The Journal of dermatologic surgery and oncology.

Small cell carcinoma presenting as an extrapulmonary neoplasm: sites of origin and response to chemotherapy.

J. Minna, A. Gazdar, P. Bunn, 1981, Journal of the National Cancer Institute.

Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy.

J. Minna, P. Bunn, D. Ihde, 1982, Cancer.

Ultrastructural appearance of cutaneous T cell lymphomas in skin, lymph nodes, and peripheral blood.

P. Bunn, A. Fischmann, G. Schechter, 1979, Cancer treatment reports.

In vitro growth of cutaneous T-cell lymphomas.

A. Gazdar, P. Bunn, E. Russell, 1979, Cancer treatment reports.

Flow cytometric analysis of megakaryocyte ploidy. Comparison with Feulgen microdensitometry and discovery that 8N is the predominant ploidy class in guinea pig and monkey marrow.

P. Bunn, R. Levine, M. Schlam, 1980, Blood.

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

P. Bunn, D. Ahnen, C. Fenoglio-Preiser, 1998, Cancer research.

Effects of neuropeptides on human lung and breast cancer cells.

P. Bunn, M. Tagawa, P. Jewett, 1992, Journal of the National Cancer Institute. Monographs.

N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents.

J. Stewart, P. Bunn, D. Chan, 2009, Advances in Experimental Medicine and Biology.

Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.

P. Bunn, D. Raben, F. Ciardiello, 2003, Lung cancer.

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

John D. Minna, Adi F. Gazdar, J. Minna, 1980, Proceedings of the National Academy of Sciences.

NCI‐navy medical oncology branch cell line data base

J. Minna, A. Gazdar, D. Carbone, 1996, Journal of cellular biochemistry. Supplement.

Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer

P. Bunn, D. Kirpotin, Paul A. Bunn, 1993 .

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.

S. Steinberg, E. Sausville, F. Kaye, 1989, The New England journal of medicine.

Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination.

J. Minna, A. Gazdar, J. Whang‐Peng, 1980, Annals of internal medicine.

Association of the human type C retrovirus with a subset of adult T-cell cancers.

W. Blattner, E. Jaffe, R. Fisher, 1983, Cancer research.

Clinical and pharmacologic studies with allylmercaptomethyl penicillin (penicillin O).

P. Bunn, W. Woodin, C. Adair, 1951, The American journal of medicine.

CUTANEOUS T-CELL LYMPHOMAS

P. Bunn, S. Broder, 1976, The Lancet.

Case reports and technical note. Nocardia asteroides meningitis. A case successfully treated with large doses of sulfadiazine and urea.

P. Bunn, R. King, J. Fitzgibbons, 1966, Journal of neurosurgery.

CLINICAL EXPERIENCES WITH KANAMYCIN *

P. Bunn, A. Baltch, Olga Krajnyak, 1958, Annals of the New York Academy of Sciences.

Pharmacological properties of hetacillin in the human.

P. Bunn, S. Milicich, J. Lunn, 1965, Antimicrobial agents and chemotherapy.

Clinical, bacteriologic, and pharmacologic observations upon cycloserine.

P. Bunn, A. Renzetti, K. W. Wright, 1956, American review of tuberculosis.

Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.

P. Bunn, S. Lamberg, Bunn Pa, 1979, Cancer treatment reports.

Some observations upon the Middlebrook-Dubos hemagglutination test in man and animals.

P. Bunn, J. Gino, C. Adair, 1952, Annals of internal medicine.

The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas

P. Bunn, K. Foon, D. Ihde, 1986, Cancer.

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

P. Bunn, D. Raben, B. Frederick, 2007, Molecular Cancer Therapeutics.

SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCER

J. Minna, A. Gazdar, P. Bunn, 1982, The Lancet.

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer

J. Minna, A. Gazdar, A. Gazdar, 1985, The Journal of experimental medicine.

Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.

Y. Miller, P. Bunn, D. Chan, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel therapies for non-small-cell lung cancer: a 2008 update.

P. Bunn, 2009, Clinical lung cancer.

Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines

Chan Zeng, F. Hirsch, P. Bunn, 2006, Molecular Cancer Research.

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Chan Zeng, Anna E Barón, F. Hirsch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal G rowth F actor R eceptor i n N on-Small-Cell L ung Carcinomas: C orrelation B etween G ene C opy N umber a nd Protein E xpression a nd I mpact o n P rognosis

F. Hirsch, P. Bunn, W. Franklin, 2003 .

The role of irinotecan combined with Cisplatin or Carboplatin in the treatment of advanced non-small-cell lung cancer.

P. Bunn, 2002, Clinical lung cancer.

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

E. Dmitrovsky, C. Henschke, F. Hirsch, 2002, Lung cancer.

Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer.

A. Gazdar, J. Whang‐Peng, P. Bunn, 1983, Cancer research.

Effective treatment of hormonally‐unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide methods of documenting tumor response and progression

J. Minna, P. Bunn, D. Ihde, 1980, Cancer.

Interferon therapy for lymphoproliferative disorders.

P. Bunn, K. Foon, M. Roth, 1988, Cancer treatment and research.

Pyoarthritis: its treatment and the role of adrenal steroids in its pathogenesis.

P. Bunn, 1957, Transactions of the American Clinical and Climatological Association.

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

K. Kelly, P. Bunn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Initial clinical and laboratory experiences with methyl phenyl isoxazolyl penicillin (P-12).

P. Bunn, J. Amberg, 1961, New York state journal of medicine.

Secondary malignancy of the thyroid gland: a case report and review of the literature.

P. Bunn, K. Shroyer, B. Haugen, 1994, Thyroid : official journal of the American Thyroid Association.

Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.

R. Makuch, J. Minna, P. Bunn, 1979, JAMA.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

M. Kris, J. Minna, I. Wistuba, 2017, Clinical Cancer Research.

Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013, Clinical Cancer Research.

Small cell lung cancer: etiology, biology, clinical features, staging, and treatment.

Y. Miller, P. Bunn, R. Cook, 1993, Current problems in cancer.

CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival

J. Minna, A. Gazdar, P. Bunn, 1979, Cancer.

Long acting penicillin preparations in infectious diseases.

P. Bunn, 1957, The Medical clinics of North America.

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

M. Kris, F. Khuri, P. Bunn, 2017, Cancer.

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

F. Hirsch, P. Bunn, W. Franklin, 2002, British Journal of Cancer.

A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC).

J. Minna, A. Gazdar, J. Whang‐Peng, 1982, Cancer genetics and cytogenetics.

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

P. Bunn, R. Doebele, D. Camidge, 2010, Lung cancer.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

D. Yankelevitz, I. Wistuba, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Worldwide overview of the current status of lung cancer diagnosis and treatment.

P. Bunn, 2012, Archives of pathology & laboratory medicine.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

J. Minna, L. Girard, A. Gazdar, 2006, Cancer research.

Small-cell lung cancer: what we know, what we need to know and the path forward

J. Minna, A. Gazdar, P. Bunn, 2017, Nature Reviews Cancer.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

P. Iyengar, H. Choy, R. Timmerman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.

Erin L. Schenk, P. Bunn, R. Doebele, 2019, Clinical lung cancer.

Pathology, Biomarkers, and Molecular Diagnostics

P. Bunn, W. Franklin, M. Varella‐Garcia, 2020 .

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Advances in lung cancer

P. Bunn, A. Dimou, J. Pacheco, 2017, Oncotarget.

Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.

P. Bunn, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

P. Bunn, D. Ihde, P. Radice, 1979, Cancer treatment reports.

Irradiated nude rat model for orthotopic human lung cancers.

P. Bunn, M. Johnston, B. Zeligman, 1991, Cancer research.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes

R. Makuch, J. Minna, A. Gazdar, 1982, Cancer.

Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.

J. Minna, A. Gazdar, P. Bunn, 1980, Cancer research.

New and emerging targeted treatments in advanced non-small-cell lung cancer

F. Hirsch, P. Bunn, Jacinta R. Wiens, 2016, The Lancet.

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

M. Kris, G. Sica, F. Khuri, 2016, Cancer.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.

J. Herman, S. Baylin, T. Byers, 2006, Cancer research.

Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk.

D. Gudbjartsson, T. Thorgeirsson, L. Kiemeney, 2011, Cancer research.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

M. Kris, G. Sica, F. Khuri, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.

E. Dmitrovsky, E. Sausville, R. Makuch, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic testing for lung cancer: reflex versus clinical selection.

P. Bunn, R. Doebele, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

K. Kelly, P. Bunn, A. Baron, 2004, Clinical Cancer Research.

Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

T. Chou, P. Bunn, L. Heasley, 1999, Cancer research.

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.

P. Bunn, W. Franklin, 2002, Seminars in oncology.

From clinical specimens to human cancer preclinical models—a journey the NCI‐cell line database—25 years later

J. Minna, J. Roth, I. Wistuba, 2019, Journal of cellular biochemistry.

Central nervous system metastases in small cell bronchogenic carcinoma.

P. Bunn, M. Matthews, J. Nugent, 1978, Seminars in oncology.

Prophylactic cranial irradiation for patients with small-cell lung cancer.

K. Kelly, P. Bunn, P A Bunn, 1995, Journal of the National Cancer Institute.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

P. Bunn, D. Gao, Jihye Kim, 2012, Cancer research.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

P. Bunn, R. Doebele, L. Gaspar, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013, PloS one.

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?

P. Bunn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.

P. Bunn, G. Weiss, D. Camidge, 2006, Oncology.

Clinical implications of cytogenetic studies in cutaneous t‐cell lymphoma (CTCL)

J. Minna, J. Whang‐Peng, P. Bunn, 1982, Cancer.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung.

J. Minna, A. Gazdar, A. Gazdar, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.

E. Gabrielson, F. Hirsch, P. Bunn, 2002, Cancer research.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZEB1-responsive genes in non-small cell lung cancer.

Elizabeth Garrett-Mayer, Michael Mitas, P. Bunn, 2011, Cancer letters.

Aggressive non-Hodgkin's lymphomas in AIDS: the University of Colorado experience.

P. Bunn, R. Gonzalez, W. Robinson, 1990, The American journal of the medical sciences.

STATUS OF KANAMYCIN IN THERAPY OF INFECTIONS

P. Bunn, J. Lunn, 1966, Annals of the New York Academy of Sciences.

Letter: Meningeal involvement in lymphoma.

P. Bunn, P. Schein, 1974, The New England journal of medicine.

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

P. Bunn, R. Doebele, D. Camidge, 2020, Frontiers in Oncology.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

T. K. Johnson, P. Bunn, W. Franklin, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.

R. Makuch, J. Minna, P. Bunn, 1981, Cancer treatment reports.

EGFR testing in lung cancer is ready for prime time.

F. Hirsch, P. Bunn, Fred R Hirsch, 2009, The Lancet. Oncology.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

R. Herbst, F. Hirsch, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.

F. Hirsch, P. Bunn, W. Franklin, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Clinical Cancer Research.

The Treatment of Subacute Bacterial Endocarditis

P. Bunn, E. Cook, 1940, Edinburgh medical journal.

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

M. Ladanyi, A. Iafrate, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A study of drug‐induced kinetic perturbations in the marrow of a patient with neuroblastoma

P. Bunn, W. Ross, S. Shackney, 1980, Cancer.

Clinical course of retrovirus-associated adult T-cell lymphoma in the United States.

W. Blattner, E. Jaffe, P. Bunn, 1983, The New England journal of medicine.

Overview of chemotherapy for small cell lung cancer.

P. Bunn, D. Carney, 1997, Seminars in oncology.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma

J. Vose, M. Czuczman, P. Bunn, 2001, Leukemia & lymphoma.

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

C. Henschke, J. Minna, F. Hirsch, 2021, Journal of Thoracic Oncology.

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Marie C. South, F. Hirsch, P. Bunn, 2009, Clinical and translational science.

Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

P. Bunn, L. Heasley, R. Nemenoff, 2009, Molecular Pharmacology.

Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

F. Hirsch, T. Mitsudomi, P. Bunn, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.

F. D'armiento, C. Mignogna, P. Bunn, 2004, Molecular cancer therapeutics.

Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

P. Bunn, D. Raben, B. Helfrich, 2004, International journal of radiation oncology, biology, physics.

“Companion Diagnostics”: Has Their Time Come and Gone?

R. Herbst, F. Hirsch, P. Bunn, 2014, Clinical Cancer Research.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014 .

Progress in research on screening and genetics in lung cancer.

F. Hirsch, P. Bunn, 2014, The Lancet. Respiratory medicine.

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

F. Hirsch, P. Bunn, N. Peled, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer in 2013: state of the art therapy for metastatic disease.

P. Bunn, F. Shepherd, L. Paz-Ares, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Chan Zeng, Adi Gazdar, J. Minna, 2006, Clinical Cancer Research.

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer

C. Obasaju, D. Ettinger, K. Kelly, 2004, Clinical Cancer Research.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced non-small-cell lung cancer with two-drug combinations.

P. Bunn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

K. Kelly, P. Bunn, D. Huffman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

P. Bunn, N. Thatcher, 2008, The oncologist.

Implementing ASCO's strategic plan 2003: diverse membership needs, prevention, and patient partnerships.

P. Bunn, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial.

R. Makuch, J. Minna, P. Bunn, 1987, Annals of internal medicine.

A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.

R. Makuch, J. Minna, N. Javadpour, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy.

R. Makuch, J. Minna, P. Bunn, 1983, The American journal of medicine.

Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer

R. Makuch, J. Minna, P. Bunn, 1983, Cancer.

Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response.

R. Makuch, J. Minna, P. Bunn, 1983, The American journal of medicine.

Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications.

R. Makuch, P. Bunn, G. Schechter, 1982, Blood.

Smoking abstinence and small cell lung cancer survival. An association.

R. Makuch, J. Minna, P. Bunn, 1980, JAMA.

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

P. Bunn, W. Franklin, M. Varella‐Garcia, 2012, Cancer.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

F. Hirsch, P. Bunn, D. Gandara, 2010, Clinical Cancer Research.

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

M. Kris, G. Sica, F. Khuri, 2022 .

Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.

J. Crowley, P. Bunn, R. Livingston, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013 .

Tissue Is the Issue : Personalized Medicine R Non-Small Cell Lung Cancer

P. Bunn, D. Gandara, M. Wynes, 2010 .

Biomarkers are here to stay for clinical research and standard care.

F. Hirsch, P. Bunn, W. Franklin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

L. Sequist, F. Hirsch, P. Bunn, 2018, Cancer.

Flow cytometric analysis of megakaryocyte ploidy. Comparison with Feulgen microdensitometry and discovery that 8N is the predominant ploidy class in guinea pig and monkey marrow

P. Bunn, R. Levine, M. Schlam, 1980 .

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Some notes about a new synthetic penicillin for staphylococcal disease.

P. Bunn, J. Amberg, R. Knight, 1960, New York state journal of medicine.

Treatment of pneumococcal pneumonia with a new penicillin: clinical observations in 25 patients.

P. Bunn, R. Knight, 1960, American Journal of the Medical Sciences.

Prostacyclin and Lung Cancer Chemoprevention

Y. Miller, P. Bunn, R. Nemenoff, 2004 .

Effects of decreasing dosages of corticotropin upon the course of ocular tuberculosis in the rabbit.

P. Bunn, F. Robinson, 1954, American review of tuberculosis.

Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck.

C E Leonard, T. Chou, P. Bunn, 1996, Cancer research.

Staphylococci: on the ubiquitous nature of human infections and their control by antimicrobial agents, singly or in combination.

P. Bunn, A. Baltch, W. Osborne, 1958, Annals of internal medicine.

Present power potions for pestilences and plagues.

P. Bunn, 1966, Transactions of the American Clinical and Climatological Association.

Ongoing and future trials of biologic therapies in lung cancer.

G. Giaccone, G. Scagliotti, P. Bunn, 2003, Lung cancer.

Applied Pharmacology of Antimicrobial AgentsPenicillins

P. Bunn, 1961 .

Human leukocyte antigens in cutaneous T cell lymphoma.

P. Bunn, S. Rosen, P. Terasaki, 1985, Journal of the American Academy of Dermatology.

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer

P. Bunn, D. Chan, Caicun Zhou, 2016, Oncotarget.

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

F. Hirsch, P. Bunn, W. Franklin, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers

Y. Miller, L. Dwyer-Nield, P. Bunn, 2019, Cancer Prevention Research.

Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.

Y. Miller, L. Dwyer-Nield, P. Bunn, 2018, Cancer research.

Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma

Y. Miller, F. Hirsch, P. Bunn, 2015, Cancer Prevention Research.

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

I. Wistuba, F. Hirsch, S. Ou, 2015, The oncologist.

MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

A. Drilon, M. Kris, P. Bunn, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adult T cell leukaemia/lymphoma.

P. Bunn, P. Kuefler, 1986, Clinics in haematology.

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.

J. Crowley, R. Ginsberg, P. Bunn, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy

P. Bunn, D. Gao, B. Helfrich, 2018, Lung cancer.

HER2/neu expression in malignant lung tumors.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Molecularly targeted therapy: when to stop and when to continue?

F. Hirsch, T. Mok, P. Bunn, 2010, The Lancet. Oncology.

Growth rates of small cell bronchogenic carcinomas

J. Minna, P. Bunn, S. Shackney, 1978, Cancer.

Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).

P. Bunn, 2002, Seminars in oncology.

Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.

P. Bunn, T. Kuzel, S. Rosen, 1990, The Journal of investigative dermatology.

The inherited nature of lung cancer: a pilot study.

K. Kelly, P. Bunn, M. Wood, 2000, Lung cancer.

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

M. Kris, P. Bunn, D. Kwiatkowski, 2021, Annals of Oncology.

Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy.

R. Makuch, J. Minna, P. Bunn, 1981, The American review of respiratory disease.

Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop.

P. Bunn, S. Lamberg, 1979, Archives of dermatology.

Altered HOX and WNT7A expression in human lung cancer.

P. Bunn, E. Brambilla, W. Franklin, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

K. Kelly, P. Bunn, 1998, Lung cancer.

Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas.

P. Bunn, A. Baltch, W. Osborne, 1960, The Journal of laboratory and clinical medicine.

DEMONSTRATION OF VIRAL ANTIGEN p24 IN CIRCULATING IMMUNE COMPLEXES OF TWO PATIENTS WITH HUMAN T-CELL LEUKAEMIA/LYMPHOMA VIRUS (HTLV) POSITIVE LYMPHOMA

P. Bunn, R. Gallo, D. Blayney, 1984, The Lancet.

A Southwest Oncology Group Phase I Study of the Sequential Combination of Recombinant Interferon-γ and Recombinant Interleukin‐2 in Patients with Cancer

P. Bunn, R. Gonzalez, E. Hersh, 1992, Journal of immunotherapy.

The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas

P. Bunn, K. Foon, D. Ihde, 1986, Cancer.

Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A).

P. Bunn, K. Foon, 1985, Seminars in oncology.

MAGE A3 antigen-specific cancer immunotherapeutic.

F. Hirsch, P. Bunn, N. Peled, 2009, Immunotherapy.

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.

P. Bunn, G. Batist, K. Cowan, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody

S. Larson, J. Minna, D. Longo, 1985 .

Sequential Use of lndium-111 Labeled Monoclonal Antibodies 96.5 and ZME-018 does not Increase Detection Sensitivity for Metastatic Melanoma

J. Murray, P. Bunn, M. Rosenblum, 1989, Clinical nuclear medicine.

The pathologic spectrum of adult T‐cell leukemia/lymphoma in the United States: Human T‐cell leukemia/lymphoma virus‐associated lymphoid malignancies

E. Jaffe, P. Bunn, M. Robert-Guroff, 1984, The American journal of surgical pathology.

A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

K. Kelly, P. Bunn, M. Wood, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bradykinin antagonists as new drugs for prostate cancer.

E. York, J. Stewart, P. Bunn, 2002, International immunopharmacology.

HTLV-I-associated diseases.

P. Bunn, 1989, The Western journal of medicine.

Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial

K. Kelly, P. Bunn, E. Vokes, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer An Analysis Based on Individual Participant Data

H. Groen, M. Parmar, M. Tsuboi, 2018 .

Fluorescence In situ Hybridization Subgroup Analysis ofTRIBUTE , a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non ^ Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008 .

Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

P. Bunn, 2006, Clinical Cancer Research.

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2006, Clinical Cancer Research.

AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels

A. Gazdar, F. Hirsch, P. Bunn, 2006 .

Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006 .

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

F. Hirsch, D. Lipson, P. Bunn, 2015, The oncologist.

Lung Cancer Fluorescence In Situ Hybridization , Immunohistochemistry , and Next-Generation Sequencing for Detection of EML 4-ALK Rearrangement in Lung Cancer

F. Hirsch, D. Lipson, P. Bunn, 2015 .

Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.

G. Piazza, P. Bunn, A. Baron, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study.

Y. Miller, F. Hirsch, P. Bunn, 2001, Journal of the National Cancer Institute.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer

Y. Miller, F. Hirsch, K. Kelly, 2009, Cancer Prevention Research.

Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction.

T. Byers, Y. Miller, F. Hirsch, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

P. Bunn, Jihye Kim, A. Tan, 2016, Clinical Cancer Research.

CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.

Erin L. Schenk, P. Bunn, B. Kavanagh, 2023, Lung cancer.

Targeting the epidermal growth factor receptor in non-small cell lung cancer.

R. Herbst, P. Bunn, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Further observations on subacute denervation and mammalian motor nerve terminal function

P. Bunn, P. Bunn, W. Riker, 1973, Neurology.

Chapter 29: Classification of Lung Cancer Histology by Gold Nanoparticle Sensors

H. Haick, F. Hirsch, P. Bunn, 2017 .

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

P. Bunn, D. Chan, Caicun Zhou, 2018, Drug design, development and therapy.

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

F. Hirsch, P. Bunn, Z. Lohinai, 2020, Molecular oncology.

Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention

William J Feser, York E Miller, Anna E Barón, 2012, Cancer Prevention Research.

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.

J. Crowley, M. Kris, R. Ginsberg, 2000, The Journal of thoracic and cardiovascular surgery.

LABORATORY AND CLINICAL STUDIES WITH CLOXACILLIN.

P. Bunn, S. Milicich, 1963, Antimicrobial Agents and Chemotherapy.

The absorption, excretion, and destruction of orally administered penicillin.

P. Bunn, W. Mcdermott, 1946, The Journal of clinical investigation.

THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH ORALLY ADMINISTERED PENICILLIN

P. Bunn, W. Mcdermott, A. C. Carter, 1945 .

The Absorption of Orally Administered Penicillin.

P. Bunn, W. Mcdermott, R. Dubois, 1946, Science.

Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury

P. Bunn, S. Ramalingam, M. Behera, 2020, Journal of Thoracic Oncology.

TWO-YEAR FOLLOW UP REPORT OF PATIENTS WITH MILIARY AND MENINGEAL TUBERCULOSIS TREATED WITH STREPTOMYCIN

P. Bunn, 1950, The American journal of the medical sciences.

The long-term toxicity and metabolic effects of isoniazid in adults.

P. Bunn, E. Mullin, K. Wright, 1953, American review of tuberculosis.

O-296 Aberrant DNA methylation and sputum atypia predict lung cancer — Preliminary report from the University of Colorado SPORE high risk cohort study

T. Byers, Y. Miller, F. Hirsch, 2003 .

The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.

P. Bunn, R. Keith, 2002, Clinical lung cancer.

Cutaneous T cell lymphomas

P. Bunn, 1994, BMJ.

Proceedings of the Workshop on Cutaneous T-Cell Lymphomas (Mycosis Fungoides and Sézary Syndrome). Introduction.

P. Bunn, S. Lamberg, 1979, Cancer treatment reports.

Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response.

J. Minna, P. Bunn, D. Ihde, 1981, AJR. American journal of roentgenology.

Observations on the administration of kanamycin to patients with tuberculosis.

P. Bunn, A. Renzetti, J. Lunn, 1959, American review of tuberculosis.

Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer.

R. Makuch, J. Minna, A. Gazdar, 1982, Bulletin du cancer.

Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

P. Bunn, B. Solomon, 2007, Cancer investigation.

Adjuvant chemotherapy for resected non-small-cell lung cancer.

P. Bunn, B. Solomon, John D Mitchell, 2005, Oncology.

Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.

P. Bunn, 2004, Clinical lung cancer.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer.

P. Bunn, R. Lilenbaum, 2003, Journal of the National Cancer Institute.

LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.

M. Kris, V. Rusch, J. Minna, 2022, Journal of Clinical Oncology.

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial

M. Kris, V. Rusch, I. Wistuba, 2019, Journal of Thoracic Oncology.

OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3

M. Kris, V. Rusch, I. Wistuba, 2019, Journal of Thoracic Oncology.

The Incidence of Brain Metastases in Stage IV ROS1‐Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

Derek E. Smith, P. Bunn, R. Camidge, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression of target molecules in lung cancer: challenge for a new treatment paradigm.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Physical Chemistry and in Vivo Tissue Heating Properties of Colloidal Magnetic Iron Oxides with Increased Power Absorption Rates

P. Bunn, D. Kirpotin, Daniel C. F. Chan, 1997 .

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort

F. Hirsch, T. Mitsudomi, P. Bunn, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed.

P. Bunn, 2004, Oncology.

Combination paclitaxel and platinum in the treatment of lung cancer: US experience.

P. Bunn, 1996, Seminars in oncology.

Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?

P. Bunn, D. Raben, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sputum Cytologic Atypia Predicts Incident Lung Cancer: Defining Latency and Histologic Specificity

T. Byers, Y. Miller, F. Hirsch, 2008, Cancer Epidemiology Biomarkers & Prevention.

Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease

T. Byers, Y. Miller, F. Hirsch, 2007, Cancer Epidemiology Biomarkers & Prevention.

67Ga accumulation in pulmonary lesions associated with bleomycin toxicity

G. Johnston, P. Bunn, S. Levenson, 1975, Cancer.

Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity.

P. Bunn, B. Solomon, 2005, Cancer treatment reviews.

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

J. Nieva, S. Ou, P. Bunn, 2013, Cancer.

Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit.

F. Hirsch, P. Bunn, W. Franklin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

F. Cappuzzo, P. Bunn, W. Franklin, 2010 .

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

LATE FOLLOWUP OF 64 PATIENTS WITH SUBACUTE BACTERIAL ENDOCARDITIS TREATED WITH PENICILLIN

P. Bunn, J. Lunn, 1962, American Journal of the Medical Sciences.

Novel agents in the treatment of lung cancer: conference summary statement.

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC).

P. Bunn, R. Doebele, L. Gaspar, 2012 .

Small-Cell Lung Cancer: Therapeutic Changes

P. Bunn, R. Dziadziuszko, P. Hirsch, 2007 .

Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution

F. Hirsch, P. Bunn, Z. Lohinai, 2020, bioRxiv.

Combined modality therapy in small cell lung cancer.

J. Jett, R. Arriagada, A. Gregor, 1994, Lung cancer.

A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption

T. K. Johnson, P. Bunn, D. G. Dienhart, 1991, Journal of Pharmacokinetics and Biopharmaceutics.

PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials

G. Scagliotti, H. Wakelee, F. Hirsch, 2021, Journal of Thoracic Oncology.

OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer

P. Bunn, A. Navarro, A. Dowlati, 2019, Journal of Thoracic Oncology.

Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers.

Edward S. Kim, P. Bunn, 2015, Clinical lung cancer.

Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

F. Hirsch, P. Bunn, D. Aisner, 2014, Clinical Cancer Research.

RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

P. Bunn, A. Navarro, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

F. Hirsch, P. Bunn, H. Popper, 2023, CA: a cancer journal for clinicians.

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008, Clinical Cancer Research.

New therapeutic strategies for lung cancer: biology and molecular biology come of age.

P. Bunn, L. Heasley, G. Johnson, 2000, Chest.

THE EFFECTS OF COLCEMID ON MOUSE BONE MARROW

P. Bunn, S. Shackney, Sharon S. Ford, 1976, Cell and tissue kinetics.

Antigens in lung cancer: clinical radio- immunolocalization in lung cancer

K. Kelly, P. Bunn, 1993 .

Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.

K. Kelly, P. Bunn, G. Weiss, 2007, Clinical Lung Cancer.

Molecular biology and early diagnosis in lung cancer.

P. Bunn, 2002, Lung cancer.

Perirectal infections in patients with small cell lung cancer.

J. Minna, P. Bunn, D. Ihde, 1981, JAMA.

Optimal therapy for elderly patients with early stage non-small cell lung cancer.

P. Bunn, 2010, American journal of respiratory and critical care medicine.

Review of therapeutic trials of carboplatin in lung cancer.

P. Bunn, 1989, Seminars in oncology.

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

F. Hirsch, K. Kelly, P. Bunn, 2006, Clinical Cancer Research.

Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.

A. Gazdar, A. Gazdar, P. Sørensen, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.

J. Minna, P. Bunn, D. Carney, 1984, Cancer treatment reports.

A phase I study of exisulind in previously treated patients with lung cancer

K. Kelly, P. Bunn, N. Mikhaeel, 2000 .

Screening and early detection

P. Bunn, H. Hansen, 2000 .

[A comparison of blood concentrations following the oral administration of tetracycline hydrochloride, tetracycline phosphate complex, and various tetracycline mixtures].

P. Bunn, G. Cronk, 1958, Antibiotic medicine & clinical therapy.

O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)

N. Hanna, P. Bunn, F. Shepherd, 2003 .

Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.

P. Bunn, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

M. Kris, J. Minna, I. Wistuba, 2023, The Journal of clinical investigation.

Absorption and clinical use of penicillin preparations given in large oral doses; a cooperative study utilizing discontinuous therapy.

Harry F. Dowling, P. Bunn, H. Dowling, 1950, Journal of the American Medical Association.

Current therapy of small cell lung cancer.

P. Bunn, 1996, Seminars in Oncology.

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

P. Sunpaweravong, K. Kelly, P. Bunn, 2006, Investigational New Drugs.

Diseases desperate grown.

P. Bunn, 2008, Journal of the National Cancer Institute.

Personalized one-two punches for lung cancer

P. Bunn, J. DeGregori, H. Scarborough, 2014, Cell Research.

Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin.

J. Minna, P. Bunn, D. Ihde, 1983, American journal of clinical oncology.

OVERVIEW OF THE BIOLOGY OF LUNG CANCER

P. Bunn, M. Kane, 1998 .

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.

E. Sausville, R. Makuch, J. Minna, 1988, Annals of internal medicine.

Lack of Association between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality

T. Byers, Y. Miller, T. Petty, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.

E. Sausville, R. Makuch, A. Gazdar, 1987, Blood.

Chickenpox complicated by severe pneumonia treated with aureomycin.

P. Bunn, J. Hammond, 1950, New York state journal of medicine.

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer

H. Groen, M. Parmar, M. Tsuboi, 2018, Chest.

Automated fluorescent analysis for drug-induced cytotoxicity assays.

A. Gazdar, P. Bunn, J. Ruckdeschel, 1986, Cancer treatment reports.

Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer.

J. Minna, J. Whang‐Peng, P. Bunn, 1982, Cancer.

description, and influence on chemotherapeutic toxicity and prognosis Bone marrow metastases in small cell carcinoma of the lung: frequency,

P. Bunn, J. Minna, D. Ihde, 2011 .

Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis.

P. Bunn, J. Minna, D. Ihde, 1979, Blood.

The role of radiation therapy in the treatment of small cell lung cancer

R. Makuch, J. Minna, P. Bunn, 1985, Cancer.

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.

G. Piazza, K. Kelly, P. Bunn, 2002, Seminars in oncology.

Operation for stage IIIa small cell lung cancer?

P. Bunn, 1990, The Annals of thoracic surgery.

MANAGEMENT AND ENDOCARDITIS WITH SYNTHETIC PENICILLINS.

P. Bunn, 1964, Antimicrobial Agents and Chemotherapy.

Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1996, Seminars in Oncology.

High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.

P. Bunn, R. Ceriani, E. Shpall, 1995, Cancer research.

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

C. Rudin, M. Kris, J. Minna, 2011 .

Biology of lung cancer

P. Bunn, M. Kane, 1998 .

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

C. Watkins, P. Bunn, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.

P. Bunn, F. Hirsch, 2012, The Lancet. Oncology.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

P. Bunn, R. Dziadziuszko, D. Gao, 2014, Clinical Cancer Research.

Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.

P. Bunn, 1999, Seminars in Oncology.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

P. Bunn, W. Franklin, A. Baron, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.

F. Cappuzzo, R. Herbst, T. Mitsudomi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

V. Devita, P. Bunn, P. Banks, 1976, Blood.

Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma.

P. Bunn, K. Foon, R. Schroff, 1986, Progress in clinical and biological research.

Myeloma Growth Kinetics: Potential Applications of Flow Cytometry

P. Bunn, O. Alabaster, 1980 .

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

M. Kris, V. Rusch, I. Wistuba, 2022, The Journal of thoracic and cardiovascular surgery.

ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.

M. Ladanyi, A. Iafrate, C. Rudin, 2012 .

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

P. Bunn, R. Dziadziuszko, M. Varella-Garcia, 2006, Clinical Cancer Research.

Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.

Y. Miller, L. Dwyer-Nield, P. Bunn, 2018, Cancer research.

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.

T. Byers, Y. Miller, T. Petty, 2005, Lung cancer.

A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases : Initial report of dose escalation and early toxicity

K. Kelly, P. Bunn, L. Gaspar, 2006 .

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

P. Bunn, N. Peled, M. Ilouze, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

288 POSTER The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines

P. Bunn, B. Helfrich, J. Haney, 2008 .

Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC).

A. Iafrate, C. Rudin, M. Kris, 2013 .

Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.

M. Kris, G. Sica, F. Khuri, 2017 .

Cancer and acquired immunodeficiency syndrome wasting syndromes: current and future therapies.

P. Bunn, 1998, Seminars in oncology.

Progress in research on screening and genetics in lung cancer.

P. Bunn, F. Hirsch, 2014, The Lancet. Respiratory medicine.

The evolution of tumor classification: a role for genomics?

P. Bunn, W. Franklin, R. Doebele, 2013, Cancer cell.

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials Lung Cancer Coronavirus Disease Clinical

G. Scagliotti, H. Wakelee, T. Mitsudomi, 2022 .

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

P. Bunn, N. Thatcher, 2008, The oncologist.